Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2011; 17(43): 4747-4756
Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4747
Table 1 Studies of renal cell cancer that include more than five patients
Ref.Yrn5-yr survivalMedian survival
Butturini et al[56]19985NR24.5 mo
La Borgne et al[15]200050%35.5 mo
Kassabian et al[11]2000567%Not reached
Ghavamian et al[59]20001181%120 mo
Hioits et al[14]200110NR4-8 yr
Faure et al[21]2001988%Not reached
Law et al[22]20031475%Not reached
Wente et al[27]200515NRNot reached
Kohler et al[61]20065100%Not reached
Crippa et al[10]2006580%Not reached
Eidit et al[57]2007788%Not reached
Varker et al[60]20075NRNot reached
Bahra et al[55]20079100%Not reached
Zerbi et al[12]20082388%Not reached
Reddy et al[54]20082145%58 mo
Tanis et al[63]200910NRNot reached
Masetti et al[35]20106NRNot reached
Konstantinidis et al[62]20102061%8.7 yr
Table 2 Prognostic factors for risk group stratification model[70]
Factors for risk groupPoor prognostic category and factors
Time from diagnosis to study entry< 12 mo
HemoglobinBelow lower limit of reference range
Lactate dehydrogenase> 1.5 x upper limit of reference range
Corrected serum calcium> 10.0 mg/dL
Previous radiotherapyYes
No. of metastatic sites≥ 2
Risk GroupNo. of factors
FavorableZero or one
PoorThree or more
Table 3 Therapeutic algorithm
Patients with clear cell renal carcinomaFirst-line therapySecond-line therapy
Without previous treatmentPrognostic grade: favorable or intermediate prognosisSunitinib orIL-2 high dose or
Bevacizumab + interferon αclinical trial
Prognostic grade: poorTemsirolimusSunitinib or
clinical trial
With previous treatmentWith cytokineSorafenibSunitinib
With multitargeted therapyEverolimusTyrosine kinase inhibitor or clinical trial
Patients with not clear cell renal carcinomaTemsirolimusSunitinib or